AVAI
Avai Bio, Inc.·Technology
0.20
4.762%(−0.01)
Close PriceLast Updated: — ET
52W L: $0.1652W H: $0.83
AVAI NEWS
prnewswire.com
May 20
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
LAS VEGAS, May 20, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA.
accessnewswire.com
May 4
Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders
KELOWNA, BC / ACCESS Newswire / May 4, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the voting results from its annual general and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held on May 4, 2026. A total of 4,135,344 common shares were represented in person or by proxy at the Meeting, representing 27.85% of the total issued and outstanding common shares of the Company.
accessnewswire.com
Apr 15
Avant Brands Announces its Annual General and Special Meeting
KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce its upcoming annual general and special meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") to be held on May 4, 2026. The notice of Meeting and the management information circular (the "Circular") is available to Shareholders on Avant's website as well as under Avant's profile on SEDAR+ at www.sedarplus.ca.
accessnewswire.com
Apr 14
Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue
KELOWNA, BC / ACCESS Newswire / April 14, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU)("Avant" or the "Company"), a leading producer of innovative and award-winning cannabis products, today released its financial results for the first quarter ended February 28, 2026 ("Q1 2026"). With an expanding global footprint, Avant has established itself as a leading Canadian producer of ultra-premium cannabis, delivering brands at a commercial volume that continues to be outpaced by market demand.
prnewswire.com
Apr 10
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned
prnewswire.com
Apr 7
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual Klotho Conference, which focuses on the future of Klotho-based therapies.
